AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2020
Jan 13, 2020
33422_dirs_2020-01-13_6f0fe136-2e59-4757-b052-868d269fc832.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-01-09
Reporting Person: OMENN GILBERT S (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-09 | Stock option (right to buy) | $2.86 | A | 40000 | Acquired | 2030-01-09 | Common Stock (40000) | Direct |
Footnotes
F1: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2020.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21